US FDA flags manufacturing lapses at Dabur facility

US FDA has flagged serious manufacturing, maintenance and data integrity concerns at a Dabur India facility in Dadra and Nagar Haveli. Inspectors reportedly observed sanitation lapses, possible contamination risks, and discrepancies in production records. The findings have raised regulatory concerns, and the company may be required to submit corrective action plans.